(Q51687421)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

title

Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

18 December 2019

main subject

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

author name string

Thomas R Gildea

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

Kenneth M Shermock

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

James K Stoller

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

language of work or name

English

0 references

publication date

5 February 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Respiratory and Critical Care Medicine

18 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

volume

167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

page(s)

1387-1392

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.

18 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Pulmonary rehabilitation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Pharmacoeconomic evaluation of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

A model for analyzing the cost of the main clinical events after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Multi-attribute health status classification systems. Health Utilities Index

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

The direct medical costs of alpha(1)-antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Formation and current results of a patient-organized registry for alpha(1)-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

When increased therapeutic benefit comes at increased cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Cost-effectiveness of captopril therapy after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Cardiopulmonary resuscitation: what cost to cheat death?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

A cost utility analysis of mammography screening in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Steroid-responsive pulmonary hypertension in a patient with Langerhans' cell granulomatosis (histiocytosis X)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Screening for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

Cost effectiveness of vaccination against pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200209-1035OC

10.1164/RCCM.200209-1035OC

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12574076%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

1 reference